

### UNAUDITED FINANCIAL RESULTS [PROVISIONAL] OF QUARTER ENDED 30TH JUNE, 2007

(Rs. in Lacs)

Particulars	Quarter Ended 30.06.2007 (Unaudited)	Quarter Ended 30.06.2006 (Unaudited)	18 Months Ended 31.03.2007 (Audited)
1. Net Sales/Income from operations	2406.73	1846.19	13427.79
2. Other Income	95.05	56.75	987.08
3. Total Expenditure			
(a) (Increase)/Decrease in Stock-in-Trade	(58.09)	68.84	(82.82)
(b) Consumption of Materials	1297.10	1256.90	8955.58
(c) Staff Cost	164.79	150.83	847.77
(d) Other Expenditure (Incl. Excise Duty)	789.67	250.21	3637.01
	2193.47	1726.78	13357.54
4. Operational Profit/(Loss) before Interest, Depreciation and Taxation	308.31	176.16	1057.33
5. Interest	93.98	110.22	585.34
6. Depreciation	39.35	43.04	213.19
7. Profit/(Loss) before Tax (4-5-6)	174.98	22.90	258.80
8. Bad Debts/Advances Written off	-	-	1,761.56
9. Loss on Investment	-	-	368.00
10. Earlier Year Taxes	-	-	(119.20)
Provision for Tax (FBT)	3.00	1.00	13.98
11. Net Profit/(Loss) (7-8-9-10)	171.98	21.90	(1765.54)
12. Paid-up Equity Share Capital (Face Value Rs.10/- per Share)	1527.50	1465.00	1527.50
Paid up Pref. Share Capital (Face Value Rs.100/- per Share)	108.57	108.57	108.57
13. Reserves excluding Revaluation Reserve	-	-	2,782.70
14. Earning Per Share on PBT (Rs.) (Basic & Diluted)	1.12	0.15	(12.53)
15. Aggregate of Non-promoter Shareholding			
- Number of Shares	11,892,735	11,742,785	11,892,785
- Percentage of Shareholding	77.85	80.16	77.86

#### Notes:

- The above results, were duly considered by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on 31st July, 2007.
- The Company has one Single Segment "Pharmaceuticals".
- Net sales/Income from operations includes Processing & Development Charges of Rs. 89.32 Lacs.
- The loss/gain on exchange fluctuation on GDR Funds for the current year will be provided at the end of the year.
- No depreciation has been provided in respect of revalued Assets for Building and Plant & Machinery during the quarter.
- One complaint received from an investor during the quarter has been resolved.
- Audit qualifications in respect of Audited Accounts for 2005-07 and management comments thereon are detailed below:
  - The deferment of R & D expenditure of Rs.1,61,14,667/- & GDR Issue expenses of Rs.91,61,542/- which is not in compliance with Accounting Standard (AS-26). The Company has explained at note No. 15 to the accounts.
  - Regarding non-provision of arrears of ex-gratia at Rs.3,66,69,307/-, the matter presently is subjudice.

For LYKA LABS LIMITED

(N. I. GANDHI)

Chairman & Managing Director

Place : Mumbai

Dated : 31st July, 2007